Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 157

Similar articles for PubMed (Select 22419641)

1.

Isoniazid vs. rifampin for latent tuberculosis infection in jail inmates: toxicity and adherence.

White MC, Tulsky JP, Lee JR, Chen L, Goldenson J, Spetz J, Kawamura LM.

J Correct Health Care. 2012 Apr;18(2):131-42. doi: 10.1177/1078345811435973. Epub 2012 Mar 14.

2.

Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study.

Page KR, Sifakis F, Montes de Oca R, Cronin WA, Doherty MC, Federline L, Bur S, Walsh T, Karney W, Milman J, Baruch N, Adelakun A, Dorman SE.

Arch Intern Med. 2006 Sep 25;166(17):1863-70.

PMID:
17000943
3.

Latent tuberculosis infection treatment for prison inmates: a randomised controlled trial.

Chan PC, Yang CH, Chang LY, Wang KF, Lu BY, Lu CY, Shao PL, Hsueh PR, Fang CT, Huang LM.

Int J Tuberc Lung Dis. 2012 May;16(5):633-8. doi: 10.5588/ijtld.11.0504. Epub 2012 Mar 8.

PMID:
22410137
4.

Treatment of latent tuberculosis infection: An update.

Lobue P, Menzies D.

Respirology. 2010 May;15(4):603-22. doi: 10.1111/j.1440-1843.2010.01751.x. Epub 2010 Apr 7. Review.

PMID:
20409026
5.

Factors associated with treatment adherence in a randomised trial of latent tuberculosis infection treatment.

Trajman A, Long R, Zylberberg D, Dion MJ, Al-Otaibi B, Menzies D.

Int J Tuberc Lung Dis. 2010 May;14(5):551-9.

PMID:
20392347
6.

Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampin.

Lardizabal A, Passannante M, Kojakali F, Hayden C, Reichman LB.

Chest. 2006 Dec;130(6):1712-7.

PMID:
17166986
7.

Assessing the impact of patient self-selection on the costs to treat latent tuberculosis infection (LTBI) with isoniazid and transitional rifampin.

Fluegge KR.

J Eval Clin Pract. 2014 Oct;20(5):685-91. doi: 10.1111/jep.12204. Epub 2014 Aug 1.

PMID:
25087583
8.

Rifampicin plus isoniazid for the prevention of tuberculosis in an immigrant population.

Jiménez-Fuentes MA, de Souza-Galvao ML, Mila Augé C, Solsona Peiró J, Altet-Gómez MN.

Int J Tuberc Lung Dis. 2013 Mar;17(3):326-32. doi: 10.5588/ijtld.12.0510.

PMID:
23407221
9.

Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial.

Jasmer RM, Saukkonen JJ, Blumberg HM, Daley CL, Bernardo J, Vittinghoff E, King MD, Kawamura LM, Hopewell PC; Short-Course Rifampin and Pyrazinamide for Tuberculosis Infection (SCRIPT) Study Investigators.

Ann Intern Med. 2002 Oct 15;137(8):640-7.

PMID:
12379063
10.

Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial.

Menzies D, Long R, Trajman A, Dion MJ, Yang J, Al Jahdali H, Memish Z, Khan K, Gardam M, Hoeppner V, Benedetti A, Schwartzman K.

Ann Intern Med. 2008 Nov 18;149(10):689-97.

PMID:
19017587
12.

Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid.

Villarino ME, Scott NA, Weis SE, Weiner M, Conde MB, Jones B, Nachman S, Oliveira R, Moro RN, Shang N, Goldberg SV, Sterling TR; International Maternal Pediatric and Adolescents AIDS Clinical Trials Group; Tuberculosis Trials Consortium.

JAMA Pediatr. 2015 Mar;169(3):247-55. doi: 10.1001/jamapediatrics.2014.3158.

PMID:
25580725
13.

Cost-effectiveness of rifampin for 4 months and isoniazid for 6 months in the treatment of tuberculosis infection.

Pina JM, Clotet L, Ferrer A, Sala MR, Garrido P, Salleras L, Domínguez A.

Respir Med. 2013 May;107(5):768-77. doi: 10.1016/j.rmed.2013.01.017. Epub 2013 Mar 13.

14.

Two-month regimen of isoniazid, rifampin and pirazinamid for latent tuberculosis infection.

Duarte R, Carvalho A, Correia A.

Public Health. 2012 Sep;126(9):760-2. doi: 10.1016/j.puhe.2012.04.008. Epub 2012 May 24. No abstract available.

PMID:
22633080
15.

Adverse effects and adherence to treatment of rifampicin 4 months vs isoniazid 6 months for latent tuberculosis: a retrospective analysis.

Fresard I, Bridevaux PO, Rochat T, Janssens JP.

Swiss Med Wkly. 2011 Aug 15;141:w13240. doi: 10.4414/smw.2011.13240.

16.

Adherence to treatment of latent tuberculosis infection in a clinical population in New York City.

Li J, Munsiff SS, Tarantino T, Dorsinville M.

Int J Infect Dis. 2010 Apr;14(4):e292-7. doi: 10.1016/j.ijid.2009.05.007. Epub 2009 Aug 4.

17.

Acceptability of short-course rifampin and pyrazinamide treatment of latent tuberculosis infection among jail inmates.

Bock NN, Rogers T, Tapia JR, Herron GD, DeVoe B, Geiter LJ.

Chest. 2001 Mar;119(3):833-7.

PMID:
11243965
18.

Treatment of latent tuberculosis infection.

Parekh MJ, Schluger NW.

Ther Adv Respir Dis. 2013 Dec;7(6):351-6. doi: 10.1177/1753465813503028. Epub 2013 Sep 20. Review.

PMID:
24056289
19.

Potential cost-effectiveness of rifampin vs. isoniazid for latent tuberculosis: implications for future clinical trials.

Esfahani K, Aspler A, Menzies D, Schwartzman K.

Int J Tuberc Lung Dis. 2011 Oct;15(10):1340-6. doi: 10.5588/ijtld.10.0575.

PMID:
22283892
20.

[Three-month course of rifampicin and isoniazid for the treatment of latent tuberculous infection].

Salinas C, Pascual Erquicia S, Diez R, Aguirre U, Egurrola M, Altube L, Capelastegui A.

Med Clin (Barc). 2010 Sep 4;135(7):293-9. doi: 10.1016/j.medcli.2010.02.038. Epub 2010 Jun 17. Spanish.

PMID:
20800162
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk